TCA
AZN icon

Transcend Capital Advisors’s AstraZeneca AZN Stock Holding History

Transcend Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Sell
6,659
-817
-11% -$154K 0.09% 220
2026
Q1 		$1.47M Sell
7,476
-124
-2% -$23.9K 0.12% 168
2025
Q4 		$1.4M Sell
7,600
-687
-8% -$120K 0.11% 173
2025
Q3 		$1.27M Sell
8,287
-851
-9% -$129K 0.09% 208
2025
Q2 		$1.28M Sell
9,138
-17,308
-65% -$2.43M 0.1% 186
2025
Q1 		$3.89M Sell
26,446
-9,864
-27% -$1.43M 0.28% 82
2024
Q4 		$4.76M Sell
36,310
-2,699
-7% -$378K 0.34% 65
2024
Q3 		$6.08M Buy
39,009
+53
+0.1% +$8.55K 0.41% 56
2024
Q2 		$6.08M Buy
38,956
+28,198
+262% +$4.24M 0.44% 48
2024
Q1 		$1.46M Buy
+10,758
New +$1.42M 0.12% 182
2023
Q3 		– Sell
-1,484
Closed -$212K – 492
2023
Q2 		$212K Sell
1,484
-127
-8% -$18.7K 0.02% 449
2023
Q1 		$224K Sell
1,611
-612
-28% -$82.3K 0.02% 426
2022
Q4 		$301K Sell
2,223
-208
-9% -$26.1K 0.03% 362
2022
Q3 		$267K Sell
2,431
-393
-14% -$49.9K 0.03% 385
2022
Q2 		$373K Buy
2,824
+101
+4% +$13.3K 0.04% 342
2022
Q1 		$361K Buy
2,723
+69
+3% +$8.28K 0.03% 372
2021
Q4 		$309K Buy
2,654
+388
+17% +$45.7K 0.03% 381
2021
Q3 		$282K Sell
2,266
-3
-0.1% -$349 0.03% 387
2021
Q2 		$271K Sell
2,269
-1,194
-34% -$131K 0.04% 271
2021
Q1 		$346K Buy
3,463
+846
+32% +$85K 0.04% 290
2020
Q4 		$262K Buy
+2,617
New +$277K 0.03% 313

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Transcend Capital Advisors's AZN Position: Q2 2026 in Review

Transcend Capital Advisors reduced its AstraZeneca (AZN) stake by 11% in Q2 2026, selling an estimated $154K and leaving 6,659 shares worth $1.26M. The position accounts for 0.09% of the portfolio, ranked #220.

Transcend Capital Advisors first reported a position in AZN in Q4 2020 and has held it in 21 quarters since. The position peaked at $6.08M in Q3 2024. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Transcend Capital Advisors held 6,659 shares of AstraZeneca worth $1.26M as of Q2 2026.
  • Transcend Capital Advisors sold 817 AstraZeneca shares in Q2 2026, an estimated $154K.
  • AstraZeneca made up 0.09% of Transcend Capital Advisors's portfolio in Q2 2026, its #220 holding.
  • Transcend Capital Advisors first reported a position in AstraZeneca in Q4 2020 and has held it in 21 quarters since.
  • Transcend Capital Advisors's AstraZeneca position peaked at $6.08M in Q3 2024.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.